32586 Federal Register / Vol. 73, No. 111 / Monday, June 9, 2008 / Notices 

Analysis and Services Office, CDC pursuant 

to Public Law 92–463. Agenda items are 

subject to change as priorities dictate. 

Contact Person for More Information: Ms. 

Amy Harris, Executive Secretary, ACIPC, 

NCIPC, CDC, 4770 Buford Highway, NE., M/ 

S F–63, Atlanta, Georgia 30341–3724, 

telephone (770) 488–4936. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both CDC and the Agency for Toxic 

Substances and Disease Registry. 

Dated: June 3, 2008. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. E8–12892 Filed 6–6–08; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Safety and Occupational Health Study 

Section (SOHSS), National Institute for 

Occupational Safety and Health, 

(NIOSH) 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the following meeting of the 

aforementioned committee: 

Times and Dates: 

8 a.m.–5 p.m., June 26, 2008 (Closed); 

8 a.m.–5 p.m., June 27, 2008 (Closed). 

Place: Embassy Suites Hotel, 1900 

Diagonal Road, Alexandria, Virginia 22314, 

Telephone (703) 684–5900, Fax (703) 684–

1403. 

Purpose: The Safety and Occupational 

Health Study Section will review, discuss, 

and evaluate grant application(s) received in 

response to the Institute’s standard grants 

review and funding cycles pertaining to 

research issues in occupational safety and 

health, and allied areas. 

It is the intent of NIOSH to support broadbased research endeavors in keeping with the 

Institute’s program goals. This will lead to 

improved understanding and appreciation for 

the magnitude of the aggregate health burden 

associated with occupational injuries and 

illnesses, as well as to support more focused 

research projects, which will lead to 

improvements in the delivery of occupational 

safety and health services, and the 

prevention of work-related injury and illness. 

It is anticipated that research funded will 

promote these program goals. 

These portions of the meeting will be 

closed to the public in accordance with 

provisions set forth in Section 552b(c)(4) and 

(6), Title 5 U.S.C., and the Determination of 

the Director, Management Analysis and 

Services Office, Centers for Disease Control 

and Prevention, pursuant to Section 10(d) 

Public Law 92–463. 

Matters To Be Discussed: The meeting will 

convene to address matters related to the 

conduct of Study Section business and to 

consider Safety and Occupational HealthRelated Grant Applications. 

Agenda items are subject to change as 

priorities dictate. 

Contact Person for More Information: Price 

Connor, PhD, NIOSH Health Scientist, 1600 

Clifton Road, NE., Mailstop E–20, Atlanta, 

Georgia 30333, Telephone (404) 498–2511, 

Fax (404) 498–2571. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities for 

both CDC and the Agency for Toxic 

Substances and Disease Registry. 

Dated: May 30, 2008. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. E8–12793 Filed 6–6–08; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

Notice of Approval of Supplemental 

New Animal Drug Application; 

Moxidectin 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is providing 

notice that it has approved a 

supplemental new animal drug 

application (NADA) filed by Fort Dodge 

Animal Health, Division of Wyeth. The 

approved NADA provides for the 

veterinary prescription use of a 

sustained-release injectable moxidectin 

formulation for prevention of 

heartworm disease and treatment of 

existing hookworm infections in dogs. 

The supplemental NADA adds animal 

safety information to product labeling. 

FOR FURTHER INFORMATION CONTACT: 

Melanie R. Berson, Center for Veterinary 

Medicine (HFV–110), Food and Drug 

Administration, 7500 Standish Pl., 

Rockville, MD 20855, 240–276–8337, email: melanie.berson@fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: Fort 

Dodge Animal Health, Division of 

Wyeth, 800 Fifth St. NW., Fort Dodge, 

IA 50501, filed a supplement to NADA 

141–189 that provides for veterinary 

prescription use of PROHEART 6 

(moxidectin) Sustained Release 

Injectable for Dogs, used for prevention 

of heartworm disease and treatment of 

existing hookworm infections. The 

supplemental NADA updates the 

warning, precaution, adverse reactions, 

and post-approval experience sections 

of product labeling. In accordance with 

section 512(i) of the Federal Food, Drug, 

and Cosmetic Act (21 U.S.C. 360b(i)) 

and 21 CFR 514.105(a) and 514.106(a), 

the Center for Veterinary Medicine is 

providing notice that this supplemental 

NADA is approved as of May 23, 2008. 

In accordance with the freedom of 

information provisions of 21 CFR part 

20 and 21 CFR 514.11(e)(2)(ii), a 

summary of safety and effectiveness 

data and information submitted to 

support approval of this application 

may be seen in the Division of Dockets 

Management (HFA–305), Food and Drug 

Administration, 5630 Fishers Lane, rm. 

1061, Rockville, MD 20852, between 9 

a.m. and 4 p.m., Monday through 

Friday. 

The agency has determined under 21 

CFR 25.33(d)(1) that this action is of a 

type that does not individually or 

cumulatively have a significant effect on 

the human environment. Therefore, 

neither an environmental assessment 

nor an environmental impact statement 

is required. 

Dated: June 2, 2008. 

Bernadette Dunham, 

Director, Center for Veterinary Medicine. 

[FR Doc. 08–1329 Filed 6–5–08; 12:00 pm] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

Cardiovascular and Renal Drugs 

Advisory Committee; Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Cardiovascular 

and Renal Drugs Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on June 25, 2008, from 8 a.m. to 5 

p.m. 

Location: Hilton Washington DC/ 

Silver Spring, Maryland Ballroom, 8727 

mstockstill on PROD1PC66 with NOTICES